McKenna's Pharmacology for Nursing, 2e

972

Index

Antifungal agents continued topical, 150, 157–160 adverse effects, 158 care considerations, 160 contraindications and cautions, 158 pharmacokinetics, 158 therapeutic actions and indications, 158 Antigens, 228, 230 Antihaemophilic agents, 751, 767–769 adverse effects, 768 care considerations, 768–769 contraindications and cautions, 768 pharmacokinetics, 768 therapeutic actions and indications, 768 Antihaemophilic factor recombinant, 751, 767–768 Antihepatitis B and C agents, 144–146 adverse effects, 145 care considerations, 146 contraindications and cautions, 145 drug–drug interactions, 145 pharmacokinetics, 144–145 therapeutic actions and indications, 144 Antihistamines, 313, 842, 852–856 adverse effects, 855 care considerations, 855–856 contraindications and cautions, 855 drug–drug interactions, 855 pharmacokinetics, 854 therapeutic actions and indications, 854 Antihypercalcaemic agents, 552, 567–569 adverse effects, 568 care considerations, 569 contraindications and cautions, 568 drug–drug interactions, 568 pharmacokinetics, 567–568 therapeutic actions and indications, 567 Antihyperlipidemic agents. See Lipid- lowering agents Antihypertensive agents, 662–676 angiotensin-converting-enzyme (ACE) inhibitors, 657, 662–665, 668–669 adverse effects, 668 care considerations, 668–669 contraindications and cautions, 668 drug–drug interactions, 668 drug–food interactions, 668 pharmacokinetics, 668 therapeutic actions and indications, 662–663 angiotensin II-receptor blockers, 665, 669–671 adverse effects, 669–670 angiotensin II-receptor, 657, 669 care considerations, 670–671 contraindications and indications, 669 drug–drug interactions, 670 pharmacokinetics, 669 therapeutic actions and indications, 669 calcium channel blockers, 665–666, 671–672 adverse effects, 671 care considerations, 672 contraindications and cautions, 671

drug–drug interactions, 671 drug–food interactions, 671–672 pharmacokinetics, 671 therapeutic actions and indications, 671 diuretic agents, 675 fixed-combination drugs, 664 sympathetic nervous system blockers, 675–676 treating hypertension, 662, 664, 667 vasodilators, 657, 666, 674–675 adverse effects, 674 care considerations, 674–675 contraindications and cautions, 674 drug–drug interactions, 674 pharmacokinetics, 674 therapeutic actions and indications, 674 Antihypocalcaemic agents, 552, 565–567 adverse effects, 565 care considerations, 567 contraindications and cautions, 565 drug–drug interactions, 566 pharmacokinetics, 565 therapeutic actions and indications, 565 Antihypotensive agents, 676–678 alpha-specific adrenergic agents, 677–678 sympathetic adrenergic agonists or vasopressors, 676–677 Anti-infective agents, 81–88 adults, 82 adverse reactions, 86–87 sensitivity testing, 81, 86 therapeutic actions, 82–85 anti-infective activity, 83 human immune response, 83–84 resistance, 81, 84–85 using, 85–86 prophylaxis, 81, 86 systemic infections, 85 Anti-inflammatory, antiarthritis and related agents, 240–255 adults, 241 antiarthritis agents, 240, 252–255 care considerations, 255 disease-modifying antirheumatic drugs, 253–255 gold compounds, 252–253 anti-inflammatory agents, 240 children, 241 non-steroidal anti-inflammatory drugs (NSAIDs), 240, 246–252 adverse effects, 250 care considerations, 252 contraindications and cautions, 249–250 drug–drug interactions, 250 pharmacokinetics, 249 gastrointestinal toxicity, 87 hypersensitivity reactions, 87 kidney damage, 86 neurotoxicity, 87 superinfections, 81, 87 children, 82 older adults, 82

therapeutic actions and indications, 246, 249 older adults, 241 salicylates, 240, 241–243, 245–246 adverse effects, 243 care considerations, 245–246 contraindications and cautions, 242–243 drug–drug interactions, 243, 245 pharmacokinetics, 242 therapeutic actions and indications, 242 salicylism, 240 sensitivity to, 242 sites of action, 243 Antimalarials, 163, 166–170 adverse effects, 168–169 care considerations, 169–170 combination drugs, 168 contraindications and cautions, 168 cultural considerations, 169 drug–drug interactions, 169 pharmacokinetics, 167–168 therapeutic actions and indications, 166–167 Antimanic drugs, 344–347 adverse effects, 345 care considerations (persons receiving lithium), 346–347 contraindications and cautions, 344–345 drug–drug interactions, 345–346 pharmacokinetics, 344 therapeutic actions and indications, 344 Antimetabolites, 190, 200–204 adverse effects, 203 care considerations, 204 contraindications and cautions, 203 drug–drug interactions, 204 pharmacokinetics, 203 therapeutic actions and indications, 200, 202 Antimigraine agents, 410–413 adults, 410 care considerations, 413 children, 410 ergot derivatives, 397, 398, 410–412 older adults, 410 triptans, 397, 398, 412 Antimycobacterials, 91, 118–121 leprostatic drugs, 118–121 adverse effects, 119–120 contraindications and cautions, 119 drug–drug interactions, 120 pharmacokinetics, 119 therapeutic actions and indications, 118–119 Antineoplastic agents, 190–223 adjunctive therapy, 191 adults, 194 alkylating agents, 190, 195–199 adverse effects, 197–198 care considerations, 198–199 antituberculosis drugs, 118 care considerations, 120–121